<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE">
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<title>Ontario (Minister of Health) v. Apotex Inc. (June 17, 2002)</title>
<style><!--
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:553679495 -2147483648 8 0 66047 0;}
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:15.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-font-kerning:0pt;
	font-weight:normal;}
h2
	{mso-style-next:Normal;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	tab-stops:1.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h3
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
h4
	{mso-style-next:Normal;
	text-align:right;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
h5
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	mso-outline-level:5;
	font-size:13.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	font-style:italic;}
h6
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	mso-outline-level:8;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	mso-outline-level:9;
	font-size:11.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{mso-style-update:auto;
	mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{mso-style-update:auto;
	mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{mso-style-next:"Index 1";
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{mso-style-next:Normal;
	text-indent:-20.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{mso-pagination:widow-orphan;
	mso-element:frame;
	mso-element-frame-width:5.5in;
	mso-element-frame-height:99.0pt;
	mso-element-frame-hspace:9.0pt;
	mso-element-wrap:auto;
	mso-element-anchor-horizontal:page;
	mso-element-left:center;
	mso-element-top:bottom;
	mso-height-rule:exactly;
	font-size:12.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToa, li.MsoToa, div.MsoToa
	{mso-style-next:Normal;
	text-indent:-10.0pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-parent:"";
	mso-pagination:widow-orphan;
	tab-stops:24.0pt 48.0pt 1.0in 96.0pt 120.0pt 2.0in 168.0pt 192.0pt 3.0in;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{mso-style-update:auto;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l9 level1 lfo24;
	tab-stops:list .25in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l8 level1 lfo29;
	tab-stops:list .25in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoList2, li.MsoList2, div.MsoList2
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoList3, li.MsoList3, div.MsoList3
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoList4, li.MsoList4, div.MsoList4
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoList5, li.MsoList5, div.MsoList5
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{mso-style-update:auto;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l7 level1 lfo25;
	tab-stops:list .5in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{mso-style-update:auto;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l6 level1 lfo26;
	tab-stops:list .75in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{mso-style-update:auto;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l5 level1 lfo27;
	tab-stops:list 1.0in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{mso-style-update:auto;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l4 level1 lfo28;
	tab-stops:list 1.25in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l3 level1 lfo30;
	tab-stops:list .5in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l2 level1 lfo31;
	tab-stops:list .75in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l1 level1 lfo3;
	tab-stops:list 60.45pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l0 level1 lfo32;
	tab-stops:list 1.25in;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{text-align:center;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-font-kerning:14.0pt;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{text-indent:-.25in;
	line-height:200%;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{text-indent:-.75in;
	mso-pagination:widow-orphan;
	background:#CCCCCC;
	mso-shading:windowtext;
	mso-pattern:gray-20 auto;
	border:none;
	mso-border-alt:solid windowtext .75pt;
	padding:0in;
	mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt;
	font-size:12.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{text-align:center;
	mso-pagination:widow-orphan;
	mso-outline-level:2;
	font-size:12.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-parent:"Body Text";
	text-indent:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-parent:"Body Text Indent";
	text-indent:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{line-height:200%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{line-height:200%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-pagination:widow-orphan;
	background:navy;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p
	{mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
address
	{mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	font-style:italic;}
pre
	{mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.headingtitle, li.headingtitle, div.headingtitle
	{mso-style-name:"heading\: title";
	mso-style-update:auto;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	tab-stops:0in .5in 1.0in 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.headingNUMBER, li.headingNUMBER, div.headingNUMBER
	{mso-style-name:"heading\: NUMBER";
	mso-style-update:auto;
	text-indent:0in;
	line-height:200%;
	mso-pagination:widow-orphan;
	mso-list:l12 level2 lfo17;
	tab-stops:0in .5in 1.0in 1.5in 2.0in 2.5in 3.0in 3.5in 4.0in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingsubtitle, li.headingsubtitle, div.headingsubtitle
	{mso-style-name:"heading\: subtitle";
	mso-style-update:auto;
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:4;
	mso-list:l12 level4 lfo17;
	tab-stops:0in .5in list 1.25in left 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingsubsubtitle, li.headingsubsubtitle, div.headingsubsubtitle
	{mso-style-name:"heading\: subsubtitle";
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:5;
	mso-list:l12 level5 lfo17;
	tab-stops:0in .5in 1.0in list 1.25in left 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingQUOTE, li.headingQUOTE, div.headingQUOTE
	{mso-style-name:"heading\: QUOTE";
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-list:l12 level3 lfo17;
	tab-stops:0in .5in 1.0in 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.headingblank, li.headingblank, div.headingblank
	{mso-style-name:"heading\: blank";
	mso-style-update:auto;
	text-indent:0in;
	line-height:200%;
	mso-pagination:widow-orphan;
	mso-list:l12 level7 lfo17;
	tab-stops:0in .5in 1.0in 1.5in 2.0in 2.5in lined 3.0in blank 3.5in 4.5in 5.0in 5.5in 6.5in 7.0in 7.5in 8.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.heading3subtitle, li.heading3subtitle, div.heading3subtitle
	{mso-style-name:"heading\: 3subtitle";
	text-indent:-.5in;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	mso-list:l12 level6 lfo17;
	tab-stops:list 1.5in;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
@page Section1
	{size:8.5in 11.0in;
	mso-header-
	mso-footer-
	mso-title-page:yes;
	mso-header: url() h1;
	mso-paper-source:2;}
div.Section1
	{page:Section1;}
@list l0
	{mso-list-id:-132;
	mso-list-type:simple;
	mso-list-template-ids:99397482;}
@list l0:level1
	{mso-level-style-link:"List Number 5";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l1
	{mso-list-id:-131;
	mso-list-type:simple;
	mso-list-template-ids:817153194;}
@list l1:level1
	{mso-level-style-link:"List Number 4";
	mso-level-tab-stop:60.45pt;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l2
	{mso-list-id:-130;
	mso-list-type:simple;
	mso-list-template-ids:-165542836;}
@list l2:level1
	{mso-level-style-link:"List Number 3";
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l3
	{mso-list-id:-129;
	mso-list-type:simple;
	mso-list-template-ids:1243241804;}
@list l3:level1
	{mso-level-style-link:"List Number 2";
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l4
	{mso-list-id:-128;
	mso-list-type:simple;
	mso-list-template-ids:-215958814;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 5";
	mso-level-text:\F0B7;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5
	{mso-list-id:-127;
	mso-list-type:simple;
	mso-list-template-ids:-1783867506;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 4";
	mso-level-text:\F0B7;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6
	{mso-list-id:-126;
	mso-list-type:simple;
	mso-list-template-ids:2043083818;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 3";
	mso-level-text:\F0B7;
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l7
	{mso-list-id:-125;
	mso-list-type:simple;
	mso-list-template-ids:-538040418;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 2";
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l8
	{mso-list-id:-120;
	mso-list-type:simple;
	mso-list-template-ids:-2056899158;}
@list l8:level1
	{mso-level-style-link:"List Number";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l9
	{mso-list-id:-119;
	mso-list-type:simple;
	mso-list-template-ids:-1555137266;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet";
	mso-level-text:\F0B7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l10
	{mso-list-id:248387907;
	mso-list-template-ids:-853636652;}
@list l10:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l10:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l10:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l10:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l10:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l10:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l10:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l10:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l10:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l11
	{mso-list-id:388502664;
	mso-list-type:simple;
	mso-list-template-ids:-1467875128;}
@list l11:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-3.5in;
	font-family:Symbol;}
@list l12
	{mso-list-id:527061025;
	mso-list-template-ids:-362882872;}
@list l12:level1
	{mso-level-number-format:none;
	mso-level-style-link:"heading\: 3subtitle";
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level2
	{mso-level-reset-level:level1;
	mso-level-style-link:"heading\: NUMBER";
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-style-link:"heading\: QUOTE";
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level4
	{mso-level-reset-level:level1;
	mso-level-style-link:"heading\: subtitle";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-style-link:"heading\: subsubtitle";
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-style-link:"heading\: 3subtitle";
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level7
	{mso-level-number-format:none;
	mso-level-style-link:"heading\: blank";
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l12:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13
	{mso-list-id:764231896;
	mso-list-template-ids:1352008676;}
@list l13:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"%3\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l13:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l13:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l14
	{mso-list-id:911693226;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l14:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l15
	{mso-list-id:1250120100;
	mso-list-template-ids:-2020592624;
	mso-list-name:QUOTE;}
@list l15:level1
	{mso-level-number-format:none;
	mso-level-text:"";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level2
	{mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level3
	{mso-level-number-format:none;
	mso-level-text:%3;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level4
	{mso-level-suffix:none;
	mso-level-text:"\(%4\)\0009";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l15:level5
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%5\)\0009";
	mso-level-tab-stop:2.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l15:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l15:level7
	{mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l15:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l15:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l16
	{mso-list-id:1273977293;
	mso-list-type:simple;
	mso-list-template-ids:-913377458;}
@list l16:level1
	{mso-level-number-format:alpha-lower;
	mso-level-text:"%1\)";
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l17
	{mso-list-id:1315601249;
	mso-list-type:simple;
	mso-list-template-ids:-52672024;}
@list l17:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l18
	{mso-list-id:1383941449;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l18:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l19
	{mso-list-id:1550385919;
	mso-list-template-ids:821708086;}
@list l19:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l19:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20
	{mso-list-id:1665664019;
	mso-list-template-ids:-1754337048;}
@list l20:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l20:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21
	{mso-list-id:1682200304;
	mso-list-template-ids:426402662;}
@list l21:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l21:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l21:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22
	{mso-list-id:1779332753;
	mso-list-template-ids:-2144417108;}
@list l22:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level2
	{mso-level-start-at:65;
	mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;
	text-decoration:none;
	text-underline:none;}
@list l22:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:.5in;}
@list l22:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l22:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l23
	{mso-list-id:1782457026;
	mso-list-type:simple;
	mso-list-template-ids:1131831968;}
@list l23:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l24
	{mso-list-id:1816682448;
	mso-list-template-ids:-784801062;}
@list l24:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l24:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l24:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-text:"%3\)";
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.5in;}
@list l24:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l24:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l24:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l24:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l24:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l24:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25
	{mso-list-id:2059817004;
	mso-list-template-ids:-1213419456;}
@list l25:level1
	{mso-level-number-format:none;
	mso-level-style-link:"heading\: subtitle";
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l25:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0in;}
@list l26
	{mso-list-id:2104912974;
	mso-list-type:simple;
	mso-list-template-ids:1385226350;}
@list l26:level1
	{mso-level-number-format:alpha-lower;
	mso-level-text:"%1\)";
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	text-indent:-.25in;}
ol
	{ul
	{-->
</style>
</head>
<body lang=EN-CA style='tab-interval:.5in' bgcolor="#FFFFFF">
<div class=Section1> 
  <p class=MsoNormal align=right style='text-align:right;'><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt'>DATE: 20020617<br>
    DOCKET:C36334</span></b></p>
  <h1><b style='mso-bidi-font-weight:normal'>COURT OF APPEAL FOR ONTARIO</b></h1>
  <p class=MsoNormal align=center style='text-align:center;mso-outline-level:
1'><b style='mso-bidi-font-weight:normal'><span style='font-size:15.0pt;
mso-bidi-font-size:10.0pt'>GOUDGE, SHARPE AND CRONK JJ.A.</span></b></p>
  <table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:
  normal'><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>BETWEEN:</span></b></p></td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <h3>MINISTER OF HEALTH, LIEUTENANT GOVERNOR IN COUNCIL and ATTORNEY GENERAL 
          OF ONTARIO</h3></td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)<br>
          </span></b><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)<br>
          </span></b><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)<br>
          )</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span
  style='mso-tab-count:1'>            </span><b style='mso-bidi-font-weight:
  normal'>J. P. Zarudny<br>
          </b></span><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span
  style="mso-spacerun: yes"> </span><span style='mso-tab-count:1'>           </span><b
  style='mso-bidi-font-weight:normal'>and J. Kendik<br>
          </b></span><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span
  style='mso-tab-count:1'>            </span><b style='mso-bidi-font-weight:
  normal'>for the appellants</b></span></p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span
  style='mso-tab-count:1'>            </span></span></p></td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <h2><b style='mso-bidi-font-weight:normal'>Appellants</b></h2></td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
  style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>- and -</span></b></p></td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span
  style='mso-tab-count:1'>            </span><b style='mso-bidi-font-weight:
  normal'>H. B. Radomski</b></span></p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=headingtitle>APOTEX INC.</p></td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)<br>
          </span></b><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)<br>
          </span></b><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span
  style='mso-tab-count:1'>            </span><b style='mso-bidi-font-weight:
  normal'>and J. M. Perrin<br>
          </b></span><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span
  style='mso-tab-count:1'>            </span><b style='mso-bidi-font-weight:
  normal'>for the respondent</b></span></p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>Respondent</span></b></p></td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)<br>
          </span></b><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0in 5.4pt 0in 5.4pt'>&nbsp;</td>
      <td width=18 valign=top style='width:13.5pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;mso-bidi-font-size:
  10.0pt'>)</span></b></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0in 5.4pt 0in 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
  style='font-size:13.0pt;mso-bidi-font-size:10.0pt'><span style='mso-tab-count:
  1'>            </span>Heard:</span></b><span style='font-size:13.0pt;
  mso-bidi-font-size:10.0pt'><span style="mso-spacerun: yes">  </span><b
  style='mso-bidi-font-weight:normal'>February 1,</b><span style="mso-spacerun:
  yes">  </span><b style='mso-bidi-font-weight:normal'>2002</b></span></p></td>
    </tr>
  </table>
  <p class=MsoNormal><b style='mso-bidi-font-weight:
normal'><span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>On appeal from 
    the order of the Divisional Court (Justices Dennis F. OLeary,<span
style="mso-spacerun: yes">  </span>Michael R. Meehan and Paul J. Cosgrove) dated 
    February 2, 2001.</span></b></p>
  <p class=headingtitle>GOUDGE J.A.:</p>
  <p class=headingNUMBER style='line-height:normal'> [1]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> This dispute arises from the administration of the publicly funded 
    drug plan in Ontario by the appellant Minister of Health. That plan provides 
    drug products at public expense to certain classes of persons such as senior 
    citizens. The prices paid by the Minister of Health for each drug product 
    are fixed by regulation and are listed in a public document called the Formulary, 
    which is both authorized and amended from time to time by regulation. </p>
  <p class=headingNUMBER style='line-height:normal'> [2]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The dispute arises because, for three sizes of a drug manufactured 
    by the respondent Apotex Inc., the Minister has refused to recommend that 
    the listed prices in the Formulary be increased to the higher prices asserted 
    by Apotex to be correct. </p>
  <p class=headingNUMBER style='line-height:normal'> [3]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The question is whether the Ministers refusal can be successfully 
    challenged on judicial review. By majority, the Divisional Court answered 
    that question in the affirmative. It declared that the Minister acted unlawfully 
    in refusing to permit the listing at the higher prices and further declared 
    that Formulary prices for these drug products are the higher prices asserted 
    by the respondent.</p>
  <p class=headingNUMBER style='line-height:normal'> [4]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> For the reasons that follow, I have come to the opposite conclusion. 
    Whether scrutinized for unlawfulness or patent unreasonableness, I think that 
    the Ministers refusal to recommend raising the listed prices in the Formulary 
    successfully withstands judicial review. I would therefore allow the appeal.</p>
  <p class=headingNUMBER style='line-height:normal;mso-list:none'><b
style='mso-bidi-font-weight:normal'>THE LEGISLATIVE CONTEXT</b></p>
  <p class=headingNUMBER style='line-height:normal'> [5]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Ontarios publicly funded drug benefit regime is regulated by two 
    pieces of legislation, the <i style='mso-bidi-font-style:normal'>Ontario Drug 
    Benefit Act</i>, R.S.O. 1990, c.O. 10 (the ODBA) and the <i
style='mso-bidi-font-style:normal'>Drug Interchangeability and Dispensing Fee 
    Act</i>, R.S.O. 1990, c.P. 23 (the DIDFA). </p>
  <p class=headingNUMBER style='line-height:normal'> [6]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The broad scheme provides that pharmacists are reimbursed by the Minister 
    of Health when they supply certain specified drugs known as listed drug products 
    to members of the eligible classes of persons. The reimbursement for each 
    drug product includes an amount known as the drug benefit price which is to 
    compensate the pharmacist for his payment to the manufacturer of that drug 
    product. It also includes a mark-up on that price and a dispensing fee.</p>
  <p class=headingNUMBER style='line-height:normal'> [7]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The ODBA gives the Lieutenant Governor in Council the power to make 
    regulations designating drugs as listed drug products. That provision is found 
    in s. 18(1)(c):</p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1>18. (1)<span style="mso-spacerun:
yes">  </span>The Lieutenant Governor in Council may make regulations,</div>
    <div class=Section1> 
      <div align="center"><br>
        </div>
    </div>
    <div class=Section1><br>
      (c)<span style="mso-spacerun:
yes">  </span>designating a product as a listed drug product where the Lieutenant 
      Governor in Council considers it advisable in the public interest to do 
      so, but a product shall not be so designated if it or its manufacturer has 
      not met the conditions described in clause (b);</div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER style='line-height:normal'> [8]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Section 18(1)(b) gives the Lieutenant Governor in Council the power 
    to prescribe by regulation the conditions to be met for listing. It has done 
    this by way of the general regulation under the ODBA Ontario, Regulation 201/96, 
    which requires that the manufacturer provide to the Minister a large quantity 
    of specified information about the drug to be listed, including the drug benefit 
    price which the manufacturer proposes. The Minister then, as a matter of practice, 
    provides a recommendation to the Lieutenant Governor in Council on the proposed 
    designation of the drug as a listed drug product. </p>
  <p class=headingNUMBER style='line-height:normal'> [9]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The schedule of all listed drug products is approved by regulation 
    and is published by the Minister in the document known as the Formulary. Because 
    of the evolving nature of pharmacology, the Formulary is updated by regulation 
    several times a year.</p>
  <p class=headingNUMBER style='line-height:normal'> [10]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The Formulary also lists the drug benefit price for each listed drug 
    product. The ODBA gives the Lieutenant Governor in Council the power to prescribe 
    by regulation the drug benefit price for each drug product listed. Section 
    22(1) of the ODBA requires that that price be the amount submitted by the 
    manufacturer and agreed to by the Minister (after considering any matter which 
    she thinks is advisable in the public interest). However, the OBDA also specifies 
    (in s. 6(1)), that if there are listed drug products which, pursuant to the 
    DIDFA, are deemed to be interchangeable with the particular drug product, 
    then the drug benefit price will be equal to the lowest drug benefit price 
    of the interchangeable drugs. Then, s. 22(3) of the ODBA provides that the 
    drug benefit price of a listed drug product may be raised or lowered by regulation 
    if the manufacturer agrees and the Lieutenant Governor in Council considers 
    it advisable in the public interest. Finally, s. 21 of the ODBA provides <i style='mso-bidi-font-style:normal'>inter 
    alia</i> that the Minister, in advising the Lieutenant Governor in Council, 
    may consider anything that the latter may consider.</p>
  <p class=headingNUMBER style='line-height:normal'> [11]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The DIDFA provides for the regulation of interchangeable drugs. Broadly 
    speaking, its purpose is to permit market access to manufacturers of generic 
    drug products which are therapeutically equivalent to the original brand of 
    the same drug products and to ensure that this market access be at a lower 
    price than the original brand. The DIDFA gives the Lieutenant Governor in 
    Council the power to make regulations designating a product as interchangeable 
    with one or more other products where the Lieutenant Governor in Council considers 
    it advisable in the public interest to do so. The general regulation under 
    DIDFA, Regulation 935 R.R.O 1990, specifies the information to be supplied 
    to the Minister as a precondition to the designation of interchangeability. 
    This information includes the drug benefit price proposed by the manufacturer, 
    which must be a certain percentage below that of the original brand of the 
    drug product. The Minister thereafter makes a recommendation to the Lieutenant 
    Governor in Council which then determines whether the drug product will be 
    designated by regulation as interchangeable. All drug products approved in 
    this way are designated as interchangeable in the Formulary as it is updated 
    from time to time. </p>
  <p class=headingNUMBER style='line-height:normal'> [12]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Thus, the Formulary sets out those drugs which have been approved 
    as listed drug products under the ODBA and groups them by drug category. For 
    any given drug category, there may be listed one or more interchangeable brands 
    approved as such under DIDFA. For each drug category, and for each interchangeable 
    brand within that category, a listed drug benefit price will appear in the 
    Formulary. </p>
  <p class=headingblank style='line-height:normal'>THE FACTS</p>
  <p class=headingNUMBER style='line-height:normal'> [13]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The drug in issue in this proceeding is the CD slow-release capsule 
    form of the medicine known as diltiazem hydrochloride. The respondents brand 
    of this form of diltiazem hydrochloride is Apo-Diltiaz CD. Its capsule sizes 
    of 120, 180 and 240 mg of this drug have been listed as three drug products 
    in the Formulary since 1997.</p>
  <p class=headingNUMBER style='line-height:normal'> [14]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In September 1998, No-Pharm, a generic drug manufacturer, applied 
    to have three drug products, its Nu-Diltiazco capsule sizes of 120, 180 and 
    240 mg, designated as listed drug products under the ODBA and as interchangeable 
    drug products under the DIDFA. As required, its proposed drug benefit prices 
    for these three drug products were lower than those listed for the Apotex 
    counterparts. The three sizes of Nu-Diltiaz CD capsule were approved for listing 
    at those lower prices in the next Formulary. </p>
  <p class=headingNUMBER style='line-height:normal'> [15]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> To meet this sort of eventuality, Apotex had previously written a 
    letter to the Ministry of Health dated February 1, 1999, authorizing the Ministry 
    to adjust downward Apotexs listed prices published in the Formulary to meet 
    the listed prices of a competitor within the same drug category. The body 
    of that letter is as follows:</p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1>This letter is to authorize the Ontario Ministry to adjust 
      Apotexs submitted or published product prices, to that of a competitors 
      price, within the same drug category.<br>
      <br>
    </div>
    <div class=Section1>If you have any questions or concerns, please do not hesitate 
      to ask.</div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER style='line-height:normal'> [16]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The Formulary which listed the three Nu-Pharm drug products for the 
    first time was approved by regulations made under the ODBA and the DIDFA on 
    February&nbsp;24, 1999 and filed on February 25, 1999. These regulations declared 
    that the new Formulary would come into force on April 15, 1999. </p>
  <p class=headingNUMBER style='line-height:normal'> [17]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Pursuant to the respondents standing authorization and as a result 
    of these three new Nu-Pharm products, the same regulations reduced the prices 
    of the three comparable Apotex drug products in the April 15, 1999 Formulary 
    from those appearing in the November 20, 1998 Formulary in order to match 
    the Nu&#8209;Pharm prices.</p>
  <p class=headingNUMBER style='line-height:normal'> [18]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> On April 8, 1999, Nu-Pharm wrote to the Ministry to advise that it 
    would not be able to supply the three new drug products and to ask that they 
    be deleted from the Formulary. That letter reached the Ministry on April 19, 
    1999. </p>
  <p class=headingNUMBER style='line-height:normal'> [19]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Apotex immediately took the position that since Nu-Pharm had never 
    in fact produced the three drug products, it did not have to meet the lower 
    prices of any competing drug products. It argued that the prices for its three 
    counterpart drug products should remain as they were in the November 20, 1998 
    Formulary.</p>
  <p class=headingNUMBER style='line-height:normal'> [20]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The Ministrys response was that the respondents prices had been 
    properly lowered in the April 15, 1999 Formulary and that it had learned of 
    the information about the Nu-Pharm drug products too late to alter the April 
    15, 1999 Formulary given that it was already in effect and that the processes 
    for obtaining the necessary regulations and for producing the Formulary took 
    several weeks and had to be undertaken well in advance of its effective date.</p>
  <p class=headingNUMBER style='line-height:normal'> [21]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Moreover, although the three Nu-Pharm drug products were thereafter 
    removed from the next Formulary (which was effective September 15, 1999), 
    the Minister refused to recommend that the listed prices in the September 
    15, 1999 Formulary for the three counterpart Apotex drug products be returned 
    to those of the November 20, 1998 Formulary. </p>
  <p class=headingNUMBER style='line-height:normal'> [22]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In doing so, the Minister relied on the Ministrys policy not to consider 
    any increase in drug benefit prices listed in the Formulary unless these increases 
    remained cost neutral to the Ministry because of an equivalent price reduction 
    in the drug benefit prices currently listed for other drug products of the 
    same manufacturer.</p>
  <p class=headingNUMBER style='line-height:normal'> [23]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> While not questioning the Ministrys right to have this cost neutral 
    policy, the respondent has maintained that this policy does not apply here 
    because Apotex is not seeking an increase in its selling price but only of 
    the erroneously listed prices of its three products. It argues that it is 
    simply seeking to return to the correct prices, namely those at which the 
    three drug products were listed before they were reduced in error in the April 
    15, 1999 Formulary, and it declined to comply with the policy of cost neutrality.</p>
  <p class=headingNUMBER style='line-height:normal'> [24]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The Ministry has declined to accept the respondents position. The 
    Minister has refused to recommend that the Lieutenant Governor in Council 
    make a regulation changing drug benefit prices for the three Apotex drug products. 
    As a result, those prices have remained unchanged from those in the April 
    15, 1999 Formulary. </p>
  <p class=headingblank style='line-height:normal'>THE DECISION APPEALED FROM</p>
  <p class=headingNUMBER style='line-height:normal'> [25]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The respondent sought judicial review of the Ministers refusal to 
    recommend that the three Apotex drug products be listed at the prices they 
    had been listed at, prior to the erroneous reduction contained in the April 
    15, 1999 Formulary. </p>
  <p class=headingNUMBER style='line-height:normal'> [26]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The majority of the Divisional Court (Cosgrove and Meehan JJ.) allowed 
    the application. They considered that the Ministers refusal constituted the 
    exercise of a statutory power under s.&nbsp;1 of the <i
style='mso-bidi-font-style:normal'>Judicial Review Procedure Act</i>, R.S.O. 1990 
    c. J-1. They then applied <i style='mso-bidi-font-style:normal'>Padfield v. 
    Minister of Agriculture, Fisheries and Food</i>, [1968] 1 All E.R. 694 and 
    determined that while the Ministers action could be reviewed only against 
    a standard of unlawfulness, the Minister had indeed acted unlawfully in two 
    respects:<span style="mso-spacerun: yes">  </span></p>
  <p class=MsoNormal style='mso-list:l26 level1 lfo21;
'> <span style='font-size:13.0pt;
mso-bidi-font-size:10.0pt'>a)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>by 
    taking into account an irrelevant consideration, namely the publication of 
    listed prices for the three Nu-Pharm products which the majority said created 
    a fiction irrelevant or extraneous to the correction sought by the respondent; 
    and</span></p>
  <p class=MsoBodyTextIndent style='line-height:normal'>b) <span
style='mso-tab-count:1'>  </span>by wholly omitting to take into account a relevant 
    consideration which the majority described this way:<span
style="mso-spacerun: yes">  </span>because Nu-Pharm had advised that it was in 
    error and had none of the three new drug products to market, there was no 
    new competitors price to trigger the Ministrys cost neutrality policy or 
    to engage the respondents authorization to the Ministry to adjust its published 
    product prices.</p>
  <p class=headingNUMBER style='line-height:normal'> [27]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In dissent, OLeary J. concluded that the Minister had not acted unlawfully 
    but had simply acted according to a bargain made with Apotex to meet the listed 
    prices of a competitor. Having done that, OLeary J. determined that the Ministry 
    had simply and properly applied its cost neutrality policy.</p>
  <p class=headingNUMBER style='line-height:normal'> [28]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In the result, the application for judicial review succeeded and the 
    declarations I have described above were issued. </p>
  <p class=headingblank style='line-height:normal'>ANALYSIS</p>
  <p class=headingNUMBER style='line-height:normal'> [29]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In my view, there are three issues that must be addressed in deciding 
    this appeal. First, some analysis is required of the administrative action 
    sought to be judicially reviewed. Second, the appropriate standard of judicial 
    review must be determined. Third, that standard must be applied to the administrative 
    action to determine the outcome of this proceeding. I will deal with each 
    of these in turn.</p>
  <p class=headingtitle>First Issue:<span style="mso-spacerun: yes">  </span>The 
    Nature of the Administrative Action</p>
  <p class=headingNUMBER style='line-height:normal'> [30]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The essence of the respondents complaint is that the error in the 
    April 15, 1999 Formulary, namely the erroneous drug benefit prices for three 
    of the respondents listed drug products, is not being corrected by replacing 
    them with the higher drug benefit prices for the same products listed in the 
    predecessor Formulary. It is the Ministers refusal to recommend such a change 
    to the Lieutenant Governor in Council that is attacked.</p>
  <p class=headingNUMBER style='line-height:normal'> [31]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In the Divisional Court, the majority proceeded on the basis that 
    the Ministers refusal to recommend was the exercise of a statutory power 
    and thus open to judicial review.</p>
  <p class=headingNUMBER style='line-height:normal'> [32]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> From one perspective, this is somewhat problematic. There is no statutory 
    provision in either the ODBA or the DIDFA requiring the Minister to make a 
    recommendation about possible changes in the drug benefit prices listed in 
    the Formulary or explicitly providing legislative directions for the making 
    of any such recommendation. Moreover, s.&nbsp;18(1)(g) of the ODBA provides 
    that it is the Lieutenant Governor in Council which prescribes by regulation 
    the drug benefit prices that appear in the Formulary. In addition, while s.&nbsp;22(3) 
    of the ODBA provides that listed drug benefit prices can be raised or lowered, 
    it is the Lieutenant Governor in Council which does this by regulation when 
    it considers it advisable to do so in the public interest.</p>
  <p class=headingNUMBER style='line-height:normal'> [33]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> However, in the circumstances of this case, I am prepared to proceed 
    on the same basis as the Divisional Court. I do so for three reasons. </p>
  <p class=headingNUMBER style='line-height:normal'> [34]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> First, in a general sense, the Minister clearly plays a central and 
    critical role in this complex statutory scheme. For most matters, the legislation 
    makes the Minister the point of contact with those involved in the scheme 
    and it is her Ministry that administers the scheme on a daily basis. For example, 
    in this case, the respondent directed its standing authorization to reduce 
    its listed prices to match its competitors to the Ministry rather than to 
    the Lieutenant Governor in Council. Moreover, where the listed drug benefit 
    price is set by agreement with the manufacturer, it is the Minister who does 
    so on behalf of the Crown. And, where the Lieutenant Governor in Council is 
    to act, s. 21 of the ODBA contemplates that it will be advised by the Minister 
    who, in doing so, may consider the same things that the Lieutenant Governor 
    in Council may consider. Thus, it is contemplated that the Minister will advise 
    on whether or not to make a regulation changing particular listed drug prices 
    and undoubtedly will be guided by what she considers advisable in the public 
    interest. In short, as a matter of reality, the ODBA puts the Minister at 
    the centre of decisions made about listed drug prices under Ontarios statutory 
    drug benefit plan, and provides some guidance to her in playing that role.</p>
  <p class=headingNUMBER style='line-height:normal'> [35]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Second, in the particular context of this case, while the change sought 
    by the respondent would be effected by the Lieutenant Governor in Council 
    making a regulation on the advice of the Minister, the Ministers refusal 
    to recommend such a change is the effective decision determining that there 
    will be no such regulation changing specific listed prices for a particular 
    drug manufacturer. Moreover, it is an effective decision about individual 
    rights rather than broad policy. Indeed, I would take the Ministers refusal 
    to be the advice to the Lieutenant Governor in Council contemplated by the 
    legislation and, since it effectively determines the respondents rights, 
    it may arguably be said to effectively constitute the exercise of a statutory 
    power.</p>
  <p class=headingNUMBER style='line-height:normal'> [36]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Third, both parties to this appeal have proceeded on the basis that 
    the Ministers refusal to recommend can be subjected to judicial review. This 
    may reflect an acceptance by those who work with the statutory drug benefit 
    scheme of several first instance decisions holding that the Ministers decision 
    to recommend or not is a statutory power of decision. See <i
style='mso-bidi-font-style:normal'>Re Apotex Inc. and Attorney General for Ontario 
    et al. </i>(1984), 47 O.R (2d) 176<span style="mso-spacerun: yes">  </span>and 
    <i style='mso-bidi-font-style:normal'>Re Apotex Inc.</i> <i
style='mso-bidi-font-style:normal'>and</i> <i style='mso-bidi-font-style:normal'>Minister 
    of Health of Ontario</i> (1989), 71 O.R. (2d) 525. However, we received no 
    argument on this issue. </p>
  <p class=headingNUMBER style='line-height:normal'> [37]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In light of these considerations, I am prepared to proceed on the 
    assumption that the Ministers refusal to recommend is subject to judicial 
    review.</p>
  <p class=headingtitle>Second Issue:<span style="mso-spacerun: yes">  </span>The 
    Appropriate Standard of Review</p>
  <p class=headingNUMBER style='line-height:normal'> [38]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> If the Ministers refusal to recommend the change sought by the respondent 
    is the subject of judicial review, the next question is the appropriate standard 
    of review to be used by the court in supervising that administrative action.</p>
  <p class=headingNUMBER style='line-height:normal'> [39]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The majority of the Divisional Court proceeded on the basis that this 
    refusal to recommend, as an exercise of ministerial discretion, can be subjected 
    to control by judicial review only if the Minister acted unlawfully as described 
    in <i style='mso-bidi-font-style:normal'>Padfield</i>, <i
style='mso-bidi-font-style:normal'>supra</i>. There, Lord Upjohn set out four 
    ways in which a Minister might act unlawfully:</p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span style='font-size:13.0pt;
mso-bidi-font-size:10.0pt'>a)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
      </span></span> <span style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>by 
      an outright refusal to consider the relevant matter;</span></div>
    <div class=Section1><span
style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>b)<span style='mso-tab-count:
1'>   </span>by misdirecting himself in point of law;</span></div>
    <div class=Section1><span
style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>c)<span style='mso-tab-count:
1'>   </span>by taking into account some wholly irrelevant or extraneous consideration; 
      or</span></div>
    <div class=Section1><span
style='font-size:13.0pt;mso-bidi-font-size:10.0pt'>d)<span style='mso-tab-count:
1'>   </span>by wholly</span> <span style='font-size:13.0pt;mso-bidi-font-size:
10.0pt'>omitting to take into account a relevant consideration.</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER style='line-height:normal'> [40]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> As I have indicated, the majority of the Divisional Court went on 
    to find that the Minister acted unlawfully in the latter two respects.</p>
  <p class=headingNUMBER style='line-height:normal'> [41]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In this court, both parties accepted the <i style='mso-bidi-font-style:
normal'>Padfield</i> basis for judicial review of the Ministers refusal to recommend 
    a change in the respondents listed prices.</p>
  <p class=headingNUMBER style='line-height:normal'> [42]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In my view, since <i style='mso-bidi-font-style:normal'>Baker v. Canada 
    (Minister of Citizenship and Immigration)</i>, [1999] 2 S.C.R. 817, we are 
    required to proceed on a somewhat different basis.</p>
  <p class=headingNUMBER style='line-height:normal'> [43]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In that case, LHeureux-Dubé J., writing for the Court, laid out a 
    new approach to the judicial review of discretionary decision-making. She 
    acknowledged that historically the exercise of ministerial discretion could 
    be judicially reviewed only on limited grounds such as those recited in <i
style='mso-bidi-font-style:normal'>Padfield</i> or bad faith or improper purpose. 
    However, she clearly felt that the time has come to determine the standard 
    of review of the substantive aspect of discretionary decisions by utilizing 
    the same framework as is employed in the judicial review of administrative 
    decisions which are more legally constrained such as those of quasi-judicial 
    tribunals. That framework is the pragmatic and functional approach to the 
    determination of the appropriate standard of review which is most fully elaborated 
    in <i style='mso-bidi-font-style:normal'>Pushpanathan v. Canada (Minister 
    of Citizenship and Immigration)</i>, [1998] 1 S.C.R. 982. </p>
  <p class=headingNUMBER style='line-height:normal'> [44]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> LHeureux-Dubé J. made clear that the adoption of the pragmatic and 
    functional approach should not be seen as reducing the level of curial deference 
    given to decisions of a highly discretionary nature but as a recognition that 
    administrative decisions vary widely in the degree of discretion left to the 
    administrative actor. A single overarching approach to determining the degree 
    of scrutiny to be given by courts to administrative actions can accommodate 
    this range of discretion. As she said in <i
style='mso-bidi-font-style:normal'>Baker, supra,</i> at para.&nbsp;56:</p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1>The pragmatic and functional approach can take into account 
      the fact that the more discretion that is left to a decision&#8209;maker, 
      the more reluctant courts should be to interfere with the manner in which 
      the decision-makers have made choices among various options.</div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER style='line-height:normal'> [45]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> <span style="mso-spacerun: yes"> </span>I take the Ministers refusal 
    to recommend to be an exercise of ministerial discretion constrained by no 
    more than what she considers advisable in the public interest. What then does 
    the pragmatic and functional approach suggest to be the appropriate standard 
    of review of this administrative action?</p>
  <p class=headingNUMBER style='line-height:normal'> [46]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> This approach calls for the consideration of a number of factors which 
    must be weighed together. See <i style='mso-bidi-font-style:normal'>Pushpanathan</i>, 
    <i style='mso-bidi-font-style:normal'>supra</i>.</p>
  <p class=headingNUMBER style='line-height:normal'> [47]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> First, there is no privative clause applicable to the Ministers action. 
    This favours a lower level of curial deference.</p>
  <p class=headingNUMBER style='line-height:normal'> [48]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Second and, in my view, most important, the fact that the administrative 
    actor here is the Minister with expertise in the administration of this specialized 
    legislative scheme suggests the need for very significant deference. As Binnie 
    J. said in <i style='mso-bidi-font-style:normal'>Mount Sinai Hospital Center 
    v. Quebec (Minister of Health and Social Services)</i>, [2001] 2 S.C.R. 281 
    at para. 58:</p>
</div>
<blockquote> 
  <blockquote>
    <div class=Section1>Decisions of Ministers of the Crown in the exercise of 
      discretionary powers in the administrative context should generally receive 
      the highest standard of deference, namely patent unreasonableness. This 
      case shows why. The broad regulatory purpose of the ministerial permit is 
      to regulate the provision of health services in the public interest. This 
      favours a high degree of deference, as does the expertise of the Minister 
      and his advisors, not to mention the position of the Minister in the upper 
      echelon of decision makers under statutory and prerogative powers. The exercise 
      of the power turns on the Ministers appreciation of the public interest, 
      which is a function of public policy in its fullest sense. </div>
  </blockquote>
</blockquote>
<div class=Section1>
  <p class=headingNUMBER style='line-height:normal'> [49]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Third, while the Ministers refusal relates directly to the rights 
    of a single party, the respondent, it involves a very broad discretion engaging 
    legal principles no more precise than the open-textured notion of what the 
    Minister considers to be advisable in the public interest. This too favours 
    greater curial deference.</p>
  <p class=headingNUMBER style='line-height:normal'> [50]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Finally, the nature of the problem facing the Minister requires an 
    appreciation of specific facts rather than an interpretation of definitive 
    legal rules. The highly discretionary and fact-based nature of the Ministers 
    refusal also points in the direction of greater deference.</p>
  <p class=headingNUMBER style='line-height:normal'> [51]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Weighing those considerations together, I conclude that the appropriate 
    standard of review is that of greatest deference, namely, patent unreasonableness.</p>
  <p class=headingtitle>Third Issue:<span style="mso-spacerun: yes">  </span>Whether 
    the Ministers Refusal is Patently Unreasonable</p>
  <p class=headingNUMBER style='line-height:normal'> [52]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In <i style='mso-bidi-font-style:normal'>Canada (A.G.) v. Public Service 
    Alliance of Canada</i>, [1993] 1 S.C.R. 941 at pp.&nbsp;963-64, Cory J. reminds 
    us that patent unreasonableness is a very strict test and an administrative 
    decision receiving the significant deference it calls for will be protected 
    from judicial intervention if it is not clearly irrational. </p>
  <p class=headingNUMBER style='line-height:normal'> [53]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In my view, the Ministers refusal is not clearly irrational. Indeed, 
    it seems to me to be quite rational. The Minister had in hand the respondents 
    standing authorization to reduce its listed prices to match its competitors. 
    A new competitor with lower prices received approval for listing in the Formulary. 
    Pursuant to the standing authorization, the listed prices of the respondents 
    counterpart drug products were reduced to match. The regulation approving 
    the Formulary with those listed prices was filed on February&nbsp;25, 1999, 
    to be effective April 15, 1999. After the effective date, the Minister learned 
    of the new competitors failure to produce and the respondents request for 
    a change in its listed prices. The Minister quite reasonably took the position 
    that it was too late to change the Formulary which had been approved in February 
    and was already in effect.</p>
  <p class=headingNUMBER style='line-height:normal'> [54]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The Minister further took the position that the respondent was asking 
    for an increase in its listed prices which could be done only by the respondent 
    complying with the Ministrys cost-neutral price increase policy. Since the 
    respondent would not comply, the Minister refused to recommend an increase 
    in its listed prices. This too seems quite reasonable. Since the April 15, 
    1999 Formulary had already been published and was lawfully in effect, the 
    respondent was indeed asking for an increase in the listed prices of its three 
    drug products. That the premise upon which the respondent had authorized these 
    new listed prices to be fixed subsequently proved wrong was surely a risk 
    for the respondents account. It was not something which made the Ministers 
    refusal patently unreasonable.</p>
  <p class=headingNUMBER style='line-height:normal'> [55]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Patent unreasonableness could, I think, also be found if the Ministers 
    refusal was the result of wholly omitting to take into account a relevant 
    consideration (see <i style='mso-bidi-font-style:normal'>Suresh v. Canada 
    (Minister of Citizenship and Immigration)</i>,<i style='mso-bidi-font-style:
normal'> </i>[2002] S.C.C. 1 at para. 29) or if it was the result of taking into 
    account some wholly irrelevant or extraneous consideration. In other words, 
    in a proper case, those two circumstances as recited in<i style='mso-bidi-font-style:
normal'> Padfield, supra, </i>could lead to a finding of patent unreasonableness.</p>
  <p class=headingNUMBER style='line-height:normal'> [56]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> While it did not do so in the context of patent unreasonableness, 
    the majority of the Divisional Court applied both factors in determining that 
    the Ministers refusal warranted judicial intervention, as I have already 
    described.</p>
  <p class=headingNUMBER style='line-height:normal'> [57]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> With respect, I think the majority erred in each case.</p>
  <p class=headingNUMBER style='line-height:normal'> [58]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The Minister did not fail to take into consideration the fact that 
    Nu-Pharm had no new product for market. The Minister simply put that fact 
    together with the timing of when it was discovered to determine that the April 
    15, 1999 Formulary was already lawfully in effect and that the respondent 
    was seeking an increase in its prices as listed in that Formulary, thus engaging 
    the Ministrys cost neutrality policy.</p>
  <p class=headingNUMBER style='line-height:normal'> [59]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Equally, it was not an irrelevant consideration for the Minister to 
    take into account the fact that Nu-Pharms prices were published in the April 
    15, 1999 Formulary. It explained why the respondents listed prices appeared 
    at the same level in the same Formulary. The respondents standing authorization 
    was to lower its published prices to match those of its competitor. The lower 
    published prices of Nu-Pharm was a very relevant consideration.</p>
  <p class=headingNUMBER style='line-height:normal'> [60]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Thus, in my view, in neither respect can the Ministers refusal be 
    said to be patently unreasonable.</p>
  <p class=headingNUMBER style='line-height:normal'> [61]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> The respondent also attacked the Ministers refusal as unfair and 
    discriminatory. Even if that characterization could make the Ministers actions 
    <i style='mso-bidi-font-style:normal'>per se</i> patently unreasonable (which 
    I doubt), it is not a characterization which applies here. The respondent 
    noted one other circumstance where the Minister had recommended a price increase 
    without applying its cost neutrality policy. However there, the lower listed 
    price originally supplied by the manufacturer was simply mistakenly submitted 
    in the beginning. Here, the problem arose because Nu-Pharm submitted listed 
    prices which were properly approved and published in the Formulary and, thereafter, 
    declared itself unable to make the product. The two circumstances are simply 
    not comparable.</p>
  <p class=headingNUMBER style='line-height:normal'> [62]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> In summary, while the Ministers refusal is challenged on a number 
    of fronts, I cannot find that any of those challenges render that refusal 
    patently unreasonable.</p>
  <p class=headingNUMBER style='line-height:normal'> [63]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> I would therefore allow the appeal, set aside the judgment below, 
    and dismiss the application for judicial review.</p>
  <p class=headingNUMBER style='line-height:normal'> [64]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> Counsel for the appellant shall deliver brief written submissions 
    on costs here and below and any proposed bill of costs within 10 days from 
    the date of this judgment. Counsel for the respondent may deliver a response, 
    if any, within 10 days thereafter.</p>
  <p class=headingNUMBER style='line-height:normal;mso-list:none'><b
style='mso-bidi-font-weight:normal'>Released:<span style="mso-spacerun: yes">  
    </span></b>June 17, 2002<span style="mso-spacerun: yes">  </span>STG</p>
  <h3 align="right"><span style='font-weight:normal'>S.T. Goudge J.A.&quot;</span></h3>
  <span style='font-size:13.0pt;mso-bidi-font-size:10.0pt;font-family:&quot;Times New Roman&quot;;
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-CA;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
  </span> 
  <h3>SHARPE J.A. (Concurring)</h3>
  <p class=headingNUMBER style='text-align:justify;line-height:normal;'> [65]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span> I agree with Goudge J.A. that the appeal should be allowed and the 
    application for judicial review dismissed. As noted by my colleague, the parties 
    have proceeded on the assumption that the Minister's refusal to recommend 
    to the Lieutenant Governor in Council that a duly enacted regulation be amended 
    is a statutory power of decision that is subject to judicial review. As the 
    point was not argued, I prefer to leave to another day the basic question 
    of the extent to which the Minister's refusal to make such a recommendation 
    is subject to judicial review, absent grounds for finding that the limits 
    of the statute or the constitution have been exceeded. Assuming, without deciding, 
    that judicial review is available, the most favourable standard of review 
    the appellants could expect in the circumstances would be patent unreasonableness. 
    I agree with Goudge J.A. that the respondent has failed to establish that 
    this decision was patently unreasonable.</p>
  <p class=headingNUMBER style='line-height:normal;mso-list:none' align="right"><b
style='mso-bidi-font-weight:normal'><span style='mso-tab-count:9'>                                                                                                            
    </span></b>Robert J. Sharpe J.A.</p>
  <p class=headingNUMBER style='line-height:normal;mso-list:none' align="right"><span
style='mso-tab-count:9'>                                                                                                            
    </span>I agree E. A. Cronk J.A.</p>
</div>
</body>
</html>
